{"id":1037499,"date":"2017-08-31T16:41:13","date_gmt":"2017-08-31T20:41:13","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/uncategorized\/puma-biotechnology-inc-pbyi-from-top-to-bottom-stocknewsjournal.php"},"modified":"2024-08-17T16:07:21","modified_gmt":"2024-08-17T20:07:21","slug":"puma-biotechnology-inc-pbyi-from-top-to-bottom-stocknewsjournal","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/puma-biotechnology-inc-pbyi-from-top-to-bottom-stocknewsjournal.php","title":{"rendered":"Puma Biotechnology, Inc. (PBYI): From Top to Bottom &#8211; StockNewsJournal"},"content":{"rendered":"<p><p>Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $92.05, down from yesterdays close by -2.23%. Given the stocks recent action, it seemed like a good time to take a closer look at the companys recent data.<\/p>\n<p>Fundamental Analysis<\/p>\n<p>Money managers are always interested in a company that can find the right recipe of fundamental data because it reflects something important going on underneath the surface. Puma Biotechnology, Inc. (PBYI) currently trades with a market capitalization of $3.36 Billion.<\/p>\n<p>The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PBYI, the company currently has $80.82 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $-158.57 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $-2.36 on a per share basis this quarter. Perhaps, that suggests something about why 94.40% of the outstanding share supply is held by institutional investors.<\/p>\n<p>Technical Analysis<\/p>\n<p>Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stocks movement on the chart, Puma Biotechnology, Inc. recorded a 52-week high of $98.85. It is now trading 6.8% off that level. The stock is trading $87.01 its 50-day moving average by -5.04%. The stock carved out a 52-week low down at $28.35.<\/p>\n<p>In recent action, Puma Biotechnology, Inc. (PBYI) has made a move of +3.20% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is outperforming the S&P 500 by 47.04, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 19.78% with $32.23 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PBYI.<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" href=\"https:\/\/stocknewsjournal.com\/2017\/08\/31\/puma-biotechnology-inc-pbyi-from-top-to-bottom-3\/\" title=\"Puma Biotechnology, Inc. (PBYI): From Top to Bottom - StockNewsJournal\" rel=\"noopener\">Puma Biotechnology, Inc. (PBYI): From Top to Bottom - StockNewsJournal<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/puma-biotechnology-inc-pbyi-from-top-to-bottom-stocknewsjournal.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1037499","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1037499"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1037499"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1037499\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1037499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1037499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1037499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}